HLAタイピングの世界市場予測:技術別(PCR、NGS、サンガーシーケンシング)、製品別(機器、試薬)、用途別(癌研究、感染症&非感染症、輸血療法)、エンドユーザー別(病院、学界、研究)

◆英語タイトル:HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer research, infectious & Non infectious diseases, Transfusion therapy), End User (Hospital, Academia and Research) - Global Forecast to 2025
◆商品コード:MD 7576
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2020年3月30日
◆ページ数:186
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥587,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

MarketsandMarkets社はHLAタイピングの世界市場が、2020年13憶ドルから2025年17憶ドルまで、年平均5.9%成長すると予測しています。本調査レポートでは、HLAタイピングの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、製品&サービス別(試薬&消耗品、機器、ソフトウェア&サービス)分析、技術別(分子アッセイ技術、非分子アッセイ技術)分析、用途別(癌研究、感染症&非感染症、輸血療法)分析、エンドユーザー別(病院、学界、研究)分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・HLAタイピングの世界市場:製品&サービス別(試薬&消耗品、機器、ソフトウェア&サービス)
・HLAタイピングの世界市場:技術別(分子アッセイ技術、非分子アッセイ技術)
・HLAタイピングの世界市場:用途別(癌研究、感染症&非感染症、輸血療法)
・HLAタイピングの世界市場:エンドユーザー別(病院、学界、研究)
・HLAタイピングの世界市場:地域別
・競争状況
・企業概要
【レポートの概要】

“The HLA typing market is projected to grow at a CAGR of 5.9% during the forecast period.”
The global HLA typing market is projected to reach USD 1.7 billion by 2025 from USD 1.3 billion in 2020, at a CAGR of 5.9%. Growth in the HLA typing market is mainly driven by factors such as the increasing number of HLA typing procedures conducted, technological advancements in the field of HLA typing, and increasing funding for research.

“Reagents & consumables accounted for the largest market share in 2019.”
Based on product and service, the HLA typing market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment accounted for the largest share of the HLA typing market in 2019. This can be attributed to the growing application horizons of molecular assay techniques in HLA typing, increasing patient emphasis on effective and early patient profiling during organ transplantation, the growing adoption of molecular diagnostic techniques in research studies, and the rising number of target procedures across major markets.

“The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019.”
On the basis of technology, the HLA typing market is segmented into molecular and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019. The growth of this segment is attributed to their benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.

“The diagnostic applications segment accounted for the largest share of the HLA typing market in 2019.”
Based on application, the HLA typing market is segmented into diagnostic and research applications. The diagnostic applications segment dominates the HLA typing market. This is attributed to technological advancements in molecular assay techniques, the increasing adoption of molecular assay procedures for pathogen encounter detection and histocompatibility cross-matching, and the growing incidence of chronic and infectious diseases.

“The commercial service providers segment accounted for the largest share of the HLA typing market in 2019.”
The HLA typing market, by end user, is segmented into commercial service providers, hospitals & surgical centers, and research laboratories & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the HLA typing market due to the ongoing rapid modernization and adoption of automation in HLA typing, growing outsourcing of R&D activities to said providers, and the increasing consolidation of diagnostic laboratories.

“North America accounted for the largest share of the global HLA typing market in 2019.”
The HLA typing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global HLA typing market in 2019. This is majorly attributed to the high adoption of advanced diagnostic technologies, increasing prevalence of target diseases in the US and Canada, and technological advancements. The rising geriatric population and growing funding and support for research are other major factors driving the growth of this regional segment.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 (42%), Tier 2 (28%), and Tier 3 (30%)
• By Designation: C-level (76%), Director-level (10%), and Others (14%)
• By Region: North America (40%), Europe (30%), APAC (22%), LATAM (6%), and the MEA (2%)

The major players operating in the HLA typing market include Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), and Hologic (US).

Research Coverage
This report studies the HLA typing market based on product and service, technology, applications, end user, and region. The report also studies the major factors affecting market growth, such as drivers, restraints, opportunities, and challenges. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions.

Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION (Page No. – 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 23)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. – 32)

4 PREMIUM INSIGHTS (Page No. – 36)
4.1 HLA TYPING MARKET: MARKET OVERVIEW
4.2 GLOBAL MARKET BREAKDOWN, BY PRODUCT & SERVICE
4.3 HLA TYPING MARKET, BY TECHNOLOGY
4.4 HLA TYPING MARKET, BY APPLICATION
4.5 HLA TYPING MARKET, BY END USER
4.6 GEOGRAPHIC SNAPSHOT OF THE HLA TYPING MARKET

5 MARKET OVERVIEW (Page No. – 40)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing number of organ transplantation procedures
5.2.1.2 Technological advancements in the field of HLA typing
5.2.1.3 Increasing public-private funding for research
5.2.1.4 Increasing prevalence of infectious & non-infectious diseases
5.2.2 RESTRAINTS
5.2.2.1 High cost of HLA typing products
5.2.2.2 Limited reimbursements for target procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Rising adoption of cross-matching and chimerism testing
5.2.3.2 Increasing public awareness about transplantation
5.2.4 CHALLENGES
5.2.4.1 Supply-demand gap between the number of organ donors and organs required annually
5.2.4.2 Dearth of skilled professionals for performing HLA typing

6 HLA TYPING MARKET, BY PRODUCT & SERVICE (Page No. – 47)
6.1 INTRODUCTION
6.2 REAGENTS & CONSUMABLES
6.2.1 EXPANDING APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES LIKE PCR AND NGS IN HLA TYPING WILL AID MARKET GROWTH
6.3 INSTRUMENTS
6.3.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING AWARENESS SUPPORT THE ADOPTION OF INSTRUMENTS
6.4 SOFTWARE & SERVICES
6.4.1 AUTOMATION AND DIGITIZATION IN LAB PROCEDURES AND RISING DEMAND FOR SPECIALIZED EQUIPMENT ARE DRIVING MARKET GROWTH

7 HLA TYPING MARKET, BY TECHNOLOGY (Page No. – 51)
7.1 INTRODUCTION
7.2 MOLECULAR ASSAY TECHNOLOGIES
7.2.1 PCR-BASED MOLECULAR ASSAYS
7.2.1.1 Sequence-specific primer-PCR
7.2.1.1.1 Expanding distribution networks of key PCR manufacturers to support market growth
7.2.1.2 Sequence-specific oligonucleotide-PCR
7.2.1.2.1 High demand of SSO-PCR is due to its benefits in donor-recipient cross-matching and disease diagnosis
7.2.1.3 Real-time PCR
7.2.1.3.1 Growing end-user preference for genome-based molecular diagnostics has supported the demand for real-time PCR
7.2.1.4 Other PCR-based molecular assays
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
7.2.2.1 Sanger sequencing
7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology drives market growth
7.2.2.2 Next-generation sequencing
7.2.2.2.1 High scalability, low turnaround time, and high-throughput capabilities have fueled the use of NGS
7.2.2.3 Other sequencing-based molecular assays
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
7.3.1 RAPID ADOPTION OF MOLECULAR ASSAY TECHNIQUES WILL HAMPER MARKET GROWTH IN THIS SEGMENT

8 HLA TYPING MARKET, BY APPLICATION (Page No. – 66)
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 DONOR-RECIPIENT CROSS-MATCHING
8.2.1.1 Need for histocompatibility cross-matching in organ transplantation drives market growth
8.2.2 INFECTIOUS DISEASE TESTING
8.2.2.1 Growing burden of infectious diseases is likely to aid market growth
8.2.3 CANCER DIAGNOSIS & PREVENTION
8.2.3.1 Clinical evidence for the success of HLA typing in cancer diagnostics will positively affect this market
8.2.4 TRANSFUSION THERAPY
8.2.4.1 Increasing evidence for the success of HLA typing in blood transfusion is a key contributor to market growth
8.2.5 OTHER DIAGNOSTIC APPLICATIONS
8.3 RESEARCH APPLICATIONS
8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING ARE DRIVING MARKET GROWTH

9 HLA TYPING MARKET, BY END USER (Page No. – 74)
9.1 INTRODUCTION
9.2 COMMERCIAL SERVICE PROVIDERS
9.2.1 RAPID MODERNIZATION AND AUTOMATION IN HLA TYPING TO SUPPORT MARKET GROWTH IN THIS SEGMENT
9.3 HOSPITALS & TRANSPLANT CENTERS
9.3.1 HIGH PURCHASING POWER OF HOSPITALS HAS ENSURED STRONG ADOPTION OF INSTRUMENTS, REAGENTS, AND CONSUMABLES
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
9.4.1 RISING GOVERNMENT SUPPORT FOR RESEARCH RELATED TO CANCER DIAGNOSIS WILL PROPEL MARKET GROWTH

10 HLA TYPING MARKET, BY REGION (Page No. – 79)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.1.1 Technological advancements in the field of HLA typing will drive market growth in the US
10.2.2 CANADA
10.2.2.1 Rising incidence of cancer will support the adoption of genomic research in Canada
10.3 EUROPE
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the European market
10.3.2 UK
10.3.2.1 Rising prevalence of autoimmune diseases drives market growth in the UK
10.3.3 FRANCE
10.3.3.1 Increasing organ rejection rate drives the need for HLA typing in France
10.3.4 ITALY
10.3.4.1 Italy’s healthcare sector has witnessed sluggish growth in recent years
10.3.5 SPAIN
10.3.5.1 Rising number of solid-organ transplantation procedures to drive market growth in Spain
10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.1.1 Supportive government regulations will drive market growth in China
10.4.2 INDIA
10.4.2.1 Increasing number of transplantation procedures drives market growth in India
10.4.3 JAPAN
10.4.3.1 Limited research and exploration in the diagnostics field to limit the adoption of HLA procedures
10.4.4 AUSTRALIA
10.4.4.1 Rising prevalence of coeliac disease in Australia to support the HLA typing market
10.4.5 SOUTH KOREA
10.4.5.1 Expansion by leading market players in South Korea will support market growth
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 BRAZIL
10.5.1.1 Brazil dominates the LATAM market
10.5.2 MEXICO
10.5.2.1 Rising medical tourism to support market growth in Mexico
10.5.3 REST OF LATAM
10.6 MIDDLE EAST AND AFRICA
10.6.1 MEA WILL HOLD A SMALLER SHARE AND GROW AT A LESSER RATE THAN MAJOR REGIONAL MARKETS

11 COMPETITIVE LANDSCAPE (Page No. – 125)
11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SCENARIO
11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
11.3.2 KEY AGREEMENTS AND COLLABORATIONS
11.3.3 KEY ACQUISITIONS
11.3.4 KEY EXPANSIONS
11.4 COMPETITIVE LEADERSHIP MAPPING
11.4.1 VISIONARY LEADERS
11.4.2 INNOVATORS
11.4.3 DYNAMIC DIFFERENTIATORS
11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES (Page No. – 131)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 THERMO FISHER SCIENTIFIC
12.2 QIAGEN
12.3 ILLUMINA
12.4 F. HOFFMAN-LA ROCHE LIMITED
12.5 BIO-RAD LABORATORIES
12.6 BECTON, DICKINSON AND COMPANY
12.7 TBG DIAGNOSTICS
12.8 FUJIREBIO
12.9 TAKARA BIO
12.10 CAREDX
12.11 OMIXON
12.12 IMMUCOR
12.13 GENOME DIAGNOSTICS
12.14 BIOFORTUNA
12.15 CREATIVE BIOLABS
12.16 OTHER COMPANIES
12.16.1 BAG HEALTHCARE
12.16.2 HISTOGENETICS
12.16.3 PACIFIC BIOSCIENCES OF CALIFORNIA
12.16.4 BGI GENOMICS
12.16.5 KRISHGEN BIOSYSTEMS

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 171)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

LIST OF TABLES (158 Tables)

TABLE 1 PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS, 2015–2018
TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
TABLE 3 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 4 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2017–2025 (USD MILLION)
TABLE 5 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2017–2025 (USD MILLION)
TABLE 6 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2017–2025 (USD MILLION)
TABLE 7 HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 8 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2017–2025 (USD MILLION)
TABLE 9 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 10 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 11 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2017–2025 (USD MILLION)
TABLE 12 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2017–2025 (USD MILLION)
TABLE 13 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 14 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 15 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 16 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2017–2025 (USD MILLION)
TABLE 17 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2017–2025 (USD MILLION)
TABLE 18 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2017–2025 (USD MILLION)
TABLE 19 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2017–2025 (USD MILLION)
TABLE 20 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2017–2025 (USD MILLION)
TABLE 21 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2017–2025 (USD MILLION)
TABLE 22 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 23 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 24 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 25 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2017–2025 (USD MILLION)
TABLE 26 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2017–2025 (USD MILLION)
TABLE 27 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2017–2025 (USD MILLION)
TABLE 28 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2017–2025 (USD MILLION)
TABLE 29 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2017–2025 (USD MILLION)
TABLE 30 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 31 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 32 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2017–2025 (USD MILLION)
TABLE 33 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2017–2025 (USD MILLION)
TABLE 34 HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 35 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 36 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2017–2025 (USD MILLION)
TABLE 37 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2017–2025 (USD MILLION)
TABLE 38 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2017–2025 (USD MILLION)
TABLE 39 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2017–2025 (USD MILLION)
TABLE 40 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2017–2025 (USD MILLION)
TABLE 41 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2017–2025 (USD MILLION)
TABLE 42 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2017–2025 (USD MILLION)
TABLE 43 HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 44 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2017–2025 (USD MILLION)
TABLE 45 HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2017–2025 (USD MILLION)
TABLE 46 HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017–2025 (USD MILLION)
TABLE 47 HLA TYPING MARKET, BY REGION, 2017–2025 (USD MILLION)
TABLE 48 NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 49 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 51 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 52 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 53 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 54 NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 55 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE US, BY TYPE, 2017–2018
TABLE 56 TARGET DISEASES INCIDENCE IN THE US, BY TYPE, 2018
TABLE 57 NEW CANCER CASES IN THE US, BY ORGAN, 2017
TABLE 58 US: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 59 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 60 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 61 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CANADA, BY TYPE, 2017–2018
TABLE 62 TARGET DISEASE INCIDENCE IN CANADA, 2017
TABLE 63 NEW CANCER CASES IN CANADA, BY ORGAN, 2018
TABLE 64 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 65 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 66 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 67 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 68 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 69 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 70 EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 71 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 72 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 73 EUROPE: HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 74 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2017–2018
TABLE 75 TARGET DISEASE INCIDENCE IN GERMANY, 2017
TABLE 76 NEW CANCER CASES IN GERMANY, BY ORGAN, 2017
TABLE 77 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 78 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 79 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 80 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE UK, BY TYPE, 2017–2018
TABLE 81 TARGET DISEASE INCIDENCE IN THE UK, 2017
TABLE 82 NEW CANCER CASES IN THE UK, BY ORGAN, 2018
TABLE 83 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 84 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 85 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 86 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, BY TYPE, 2017–2018
TABLE 87 NEW CANCER CASES IN FRANCE, BY ORGAN, 2018
TABLE 88 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 89 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 90 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 91 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 92 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 93 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 94 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 95 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 96 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 97 ROE: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 98 ROE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 99 ROE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 100 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 101 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 102 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 103 ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 104 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 105 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 106 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 107 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, BY TYPE, 2017–2018
TABLE 108 NEW CANCER CASES IN CHINA, BY ORGAN, 2018
TABLE 109 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 110 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 111 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 112 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, BY TYPE, 2017–2018
TABLE 113 NEW CANCER CASES IN INDIA, BY ORGAN, 2018
TABLE 114 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 115 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 116 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 117 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, BY TYPE, 2017–2018
TABLE 118 NEW CANCER CASES IN JAPAN, BY ORGAN, 2018
TABLE 119 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 120 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 121 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 122 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, BY TYPE, 2017–2018
TABLE 123 NEW CANCER CASES IN AUSTRALIA, BY ORGAN, 2018
TABLE 124 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 125 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 126 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 127 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 128 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 129 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 130 ROAPAC: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 131 ROAPAC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 132 ROAPAC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 133 LATAM: HLA TYPING MARKET, BY COUNTRY, 2017–2025 (USD MILLION)
TABLE 134 LATAM: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 135 LATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 136 LATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 137 LATAM: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 138 LATAM: HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 139 LATAM: HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)
TABLE 140 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, BY TYPE, 2017–2018
TABLE 141 NEW CANCER CASES IN BRAZIL, BY ORGAN, 2018
TABLE 142 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 143 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 144 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 145 SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, BY TYPE, 2017–2018
TABLE 146 NEW CANCER CASES IN MEXICO, BY ORGAN, 2018
TABLE 147 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 148 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 149 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 150 ROLATAM: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 151 ROLATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 152 ROLATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 153 MEA: HLA TYPING MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION)
TABLE 154 MEA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 155 MEA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017–2025 (USD MILLION)
TABLE 156 MEA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017–2025 (USD MILLION)
TABLE 157 MEA: HLA TYPING MARKET, BY APPLICATION, 2017–2025 (USD MILLION)
TABLE 158 MEA: HLA TYPING MARKET, BY END USER, 2017–2025 (USD MILLION)

LIST OF FIGURES (33 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: HLA TYPING MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 HLA TYPING MARKET SHARE, BY PRODUCT, 2019 VS. 2025 (USD MILLION)
FIGURE 7 HLA TYPING MARKET SHARE, BY APPLICATION, 2019 VS. 2025
FIGURE 8 HLA TYPING MARKET, BY TECHNOLOGY, 2019–2025 (USD MILLION)
FIGURE 9 HLA TYPING MARKET, BY END USER
FIGURE 10 HLA TYPING MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT
FIGURE 11 INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES ACROSS THE GLOBE IS SUPPORTING THE GROWTH OF THE MARKET
FIGURE 12 REAGENTS & CONSUMABLES HELD THE LARGEST SHARE OF THE MARKET
FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO HOLD LARGEST SHARE OF THE GLOBAL MARKET
FIGURE 14 DIAGNOSTIC APPLICATIONS HOLD THE MAJOR SHARE OF THE MARKET, BY APPLICATION
FIGURE 15 COMMERCIAL SERVICE PROVIDERS SEGMENT WILL REGISTER THE HIGHEST CAGR
FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 17 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 18 NORTH AMERICA: HLA TYPING MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC: HLA TYPING MARKET SNAPSHOT
FIGURE 20 PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
FIGURE 21 THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING MARKET, AS OF 2019
FIGURE 22 HLA TYPING MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 23 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
FIGURE 24 QIAGEN: COMPANY SNAPSHOT (2018)
FIGURE 25 ILLUMINA: COMPANY SNAPSHOT (2019)
FIGURE 26 F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 27 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
FIGURE 28 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2018)
FIGURE 29 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)
FIGURE 30 FUJIREBIO: COMPANY SNAPSHOT (2016)
FIGURE 31 TAKARA: COMPANY SNAPSHOT (2019)
FIGURE 32 CAREDX: COMPANY SNAPSHOT (2018)
FIGURE 33 IMMUCOR: COMPANY SNAPSHOT (2016)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[HLAタイピングの世界市場予測:技術別(PCR、NGS、サンガーシーケンシング)、製品別(機器、試薬)、用途別(癌研究、感染症&非感染症、輸血療法)、エンドユーザー別(病院、学界、研究)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆